ReviewPatient related outcome measures2019
Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies.
Review in Patient related outcome measures, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus.Rheumatology (Oxford, England) · 2021Pooled it
- Diffuse neuropsychiatric lupus: Clinical evidence, immune-mediated mechanisms, and therapeutic insights.Seminars in immunology · 2025Review
- Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence.Patient related outcome measures · 2023Review
- Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2022Article
- State of the art and future directions in assessing the quality of life in rare and complex connective tissue and musculoskeletal diseases.Frontiers in medicine · 2022Review
- Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research.Nature reviews. Rheumatology · 2021Review
- Review
- Contribution of abnormal BMI to adverse health-related quality of life outcomes after a 52-week therapy in patients with SLE.Rheumatology (Oxford, England) · 2021Article
- Use of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus.Journal of clinical medicine · 2020Article
- Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis.BMC nephrology · 2019Article
- Resolution of inflammation: from basic concepts to clinical application.Seminars in immunopathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune, multisystem rheumatic disease with significant impact on health-related quality of life (HRQoL). Patient-reported outcomes (PROs) provide valuable data on patient perceptions across a variety of domains, such as HRQoL, pain, fatigue, and depression. The measurement and results of PROs with respect to HRQoL in randomized controlled trials (RCTs) on belimumab (B-lymphocyte stimulator inhibitor) in SLE are reviewed here, including BLISS-52 and BLISS-76, as well as publications related to belimumab trials that included HRQoL data. Other trials that evaluated belimumab did not include HRQoL data and were therefore not included in the analysis. The BLISS-52 and BLISS-76 RCTs met their primary endpoints and demonstrated improvements in PROs, measured by the 36-item Short Form Health Survey, EuroQol 5 Dimensions, and Functional Assessment of Chronic Illness Therapy-Fatigue Scale. Belimumab was shown overall to improve PROs in adult autoantibody-positive lupus patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.